This trial is active, not recruiting.

Condition extrahepatic cholangiocarcinoma
Treatment surgical treatment
Sponsor First Affiliated Hospital, Sun Yat-Sen University
Collaborator Guangdong Province, Department of Science and Technology
Start date July 2006
End date April 2014
Trial size 20 participants
Trial identifier NCT02103179, k0113011-2013ECC


The investigators study the VEGF signaling in ECC cell lines,patients and its mechanism in ECC growth, proliferation and apoptosis.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective retrospective
Extrahepatic cholangiocarcinoma patients treated by surgical treatment
surgical treatment
all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.

Primary Outcomes

the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.
time frame: the day when conducting surgery (day 1)

Eligibility Criteria

Male or female participants from 16 years up to 80 years old.

Inclusion Criteria: 1. Extrahepatic cholangiocarcinoma patients diagnosed through biopsy; two or more dynamic imagine with a diagnosis of Extrahepatic cholangiocarcinoma 2. Child-Pugh A or B 3. well preserved renal and hematopoietic Function 4. receive surgical therapy 5. achieve complete section accessed by contrast-enhanced CT Exclusion Criteria: 1. incomplete section 2. remote metastasis 3. Child-Pugh C 4. combination with other hepatobiliary disease 5. suffer from other tumors concurrently or in last five years

Additional Information

Official title VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway
Principal investigator Ming Kuang, MD
Description Several studies have documented the elevated expression of VEGF, VEGFR1 and VEGFR2 in cancer cell lines. Another study observed a sequential elevation of VEGF in low-grade dysplasia, high-grade dysplasia and early stage liver cancer. Clinical analyses have discovered the high expression of VEGF is correlated with tumor progression, vascular invasion, distal metastasis and poor prognosis. However, few studies have been conducted to investigate the VEGF signaling in ECC cells and its possible mechanism in regulating ECC growth.Therefore,we try to clarify the mechanism of VEGF signal in ECC growth,proliferation and apoptosis.
Trial information was received from ClinicalTrials.gov and was last updated in March 2014.
Information provided to ClinicalTrials.gov by First Affiliated Hospital, Sun Yat-Sen University.